Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1935]

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra...

EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )

ASCO GU 2026: Updates in renal cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in renal cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in bladder cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in bladder cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez...

ASCO GU 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez and Dr Guillermo de Velasco )

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or...

Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA

$Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma ( Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA )$

Tepotinib in second line NSCLC treatment

Dr Antonio Passaro and Prof Raffaele Califano

Tepotinib in second line NSCLC treatment ( Dr Antonio Passaro and Prof Raffaele Califano )

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2...

Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer ( Dr Erika Hamilton - Sarah Cannon Research Institute, Nashville, USA )

Sacituzumab govitecan improves quality of life in untreated advanced TNBC

Dr Kevin Punie - Ziekenhuis aan de Stroom, Antwerp, Belgium

Sacituzumab govitecan improves quality of life in untreated advanced TNBC ( Dr Kevin Punie - Ziekenhuis aan de Stroom, Antwerp, Belgium )

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to...

Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of...

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab ( Prof Wojciech Jurczak - Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland )

More from ecancer